Journal of the Formosan Medical Association = Taiwan yi zhi · 2026
Comparison of the efficacy of 14-day sequential therapy and 10-day bismuth quadruple therapy in the second line therapy for Helicobacter pylori infection- A multi-center randomized trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Tsung-Hua, Lee Ji-Yuh, Yu Jian-Jyun, Kuo Chia-Chi, Chiu Min-Chin, Hu Wen-Hao, Tsai Min-Horn, Chen Po-Yueh, Chou Chu-Kuang, Chen Chi-Yi, Bair Ming-Jong, Cheng Hsiu-Chi, Chen Mei-Jyh, Chen Chieh-Chang, Wu Ming-Shiang, Liou Jyh-Ming, Fang Yu-Jen, Taiwan Gastrointestinal Disease and Helicobacter Consortium
Аннотация
BACKGROUND: Whether extending treatment duration and using high-dose esomeprazole can improve the efficacy of sequential therapy as second-line treatment for Helicobacter pylori (H. pylori) infection remains uncertain. We aimed to compare the efficacy and tolerability of optimized 14-day sequential therapy (ST14) and 10-day bismuth quadruple therapy (BQ10), both containing high-dose esomeprazole, as second-line treatment after failure of standard triple therapy.
METHODS: In this multicenter, open-label, randomized trial conducted at six hospitals in Taiwan, adult patients (≥20 years) with confirmed H. pylori infection who failed first-line standard triple therapy were randomly assigned to receive ST14 or BQ10. Both regimens included esomeprazole 40 mg twice daily. The primary outcome was eradication rate assessed by ^13C-urea breath test using intention-to-treat (ITT) and per-protocol (PP) analyses. Secondary outcomes included adverse events, treatment adherence, and short-term changes in metabolic parameters. Antibiotic resistance and 23S ribosomal RNA mutations were assessed in available isolates.
CLINICALTRIALS: gov: NCT03208426.
RESULTS: A total of 155 patients were randomized (ST14, n = 76; BQ10, n = 79). Eradication rates were significantly lower with ST14 than with BQ10 in both ITT analysis (60.5% vs. 87.3%, P < 0.0001) and PP analysis (62.2% vs. 98.6%, P < 0.0001). ST14 was associated with fewer adverse events than BQ10 (39.5% vs. 62.0%, P = 0.008), while treatment adherence was high and comparable between groups. The eradication rate of ST14 was 80% in strains harboring 23S ribosomal RNA mutations and 99% in those without mutations (P < 0.0001). No clinically meaningful differences in metabolic parameters were observed at 8 weeks.
CONCLUSIONS: BQ10 provides superior eradication efficacy compared with ST14 as second-line treatment for H. pylori infection, despite higher rates of adverse events. Sequential therapy with high-dose esomeprazole should not be used empirically as second-line therapy.
METHODS: In this multicenter, open-label, randomized trial conducted at six hospitals in Taiwan, adult patients (≥20 years) with confirmed H. pylori infection who failed first-line standard triple therapy were randomly assigned to receive ST14 or BQ10. Both regimens included esomeprazole 40 mg twice daily. The primary outcome was eradication rate assessed by ^13C-urea breath test using intention-to-treat (ITT) and per-protocol (PP) analyses. Secondary outcomes included adverse events, treatment adherence, and short-term changes in metabolic parameters. Antibiotic resistance and 23S ribosomal RNA mutations were assessed in available isolates.
CLINICALTRIALS: gov: NCT03208426.
RESULTS: A total of 155 patients were randomized (ST14, n = 76; BQ10, n = 79). Eradication rates were significantly lower with ST14 than with BQ10 in both ITT analysis (60.5% vs. 87.3%, P < 0.0001) and PP analysis (62.2% vs. 98.6%, P < 0.0001). ST14 was associated with fewer adverse events than BQ10 (39.5% vs. 62.0%, P = 0.008), while treatment adherence was high and comparable between groups. The eradication rate of ST14 was 80% in strains harboring 23S ribosomal RNA mutations and 99% in those without mutations (P < 0.0001). No clinically meaningful differences in metabolic parameters were observed at 8 weeks.
CONCLUSIONS: BQ10 provides superior eradication efficacy compared with ST14 as second-line treatment for H. pylori infection, despite higher rates of adverse events. Sequential therapy with high-dose esomeprazole should not be used empirically as second-line therapy.